BCRX · Biocryst Pharmaceuticals Inc · Webcasts, Transcripts & Audio
$7.61
-0.07 (-0.91%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.96B
Shares
257.30M
Volume · Nov 13
2.32M
Avg daily vol (3M)
4.87M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Biocryst Pharmaceuticals Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Biocryst Pharmaceuticals Inc (BCRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-01
Biocryst Pharmaceuticals Inc (BCRX) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-18
Biocryst Pharmaceuticals Inc (BCRX) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
Biocryst Pharmaceuticals Inc (BCRX) Q3 2026 Earnings Call Transcript
Confident tone
Guidance and revenue dynamics
Orlodeo growth
CareMed pharmacy transition
Revenue
$180.29M
▲ 13.1% YoY Diluted EPS
$0.14
▲ 133.3% YoY Gross margin
99.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-15
Biocryst Pharmaceuticals Inc (BCRX) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Biocryst Pharmaceuticals Inc (BCRX) Q2 2026 Earnings Call Transcript
Confident tone
Pediatric launch (Orladeyo pellets)
Demand momentum and new prescribers
Patient retention / stickiness
Revenue
$218.25M
▲ 33.6% YoY Diluted EPS
$0.30
▲ 1400% YoY Gross margin
98.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Biocryst Pharmaceuticals Inc (BCRX) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Biocryst Pharmaceuticals Inc (BCRX) Q1 2026 Earnings Call Transcript
Confident tone
ORLADEYO commercial performance
Navenibart / ALPHA-ORBIT Phase 3
Pediatric pellet launch and manufacturing delay
Revenue
$156.41M
▲ 7.5% YoY Diluted EPS
$-2.98
Gross margin
96.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Biocryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Transcript
Confident tone
HAE market structure and competition
ORLADEYO commercial performance and growth
Navenibart Phase III program
Revenue
$406.56M*
▲ 209.1% YoY Gross margin
97.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-14
Biocryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Transcript
Confident tone
ORLADEYO revenue growth and guidance raise
BCX17725 for Netherton syndrome
Astria acquisition and navenibart asset
Revenue
$159.40M
▲ 36.1% YoY Diluted EPS
$0.06
Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Biocryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Transcript
Confident tone
ORLADEYO commercial momentum
CEO succession and BioCryst 2.0 / BD strategy
Pipeline programs (Netherton, DME)
Revenue
$163.35M
▲ 49.4% YoY Diluted EPS
$0.02
Gross margin
98.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Biocryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Transcript
Confident tone
ORLADEYO commercial performance
Profitability and financial strength
Pipeline progress (BCX17725, avoralstat)
Revenue
$145.53M
▲ 56.9% YoY Diluted EPS
$0.00
Gross margin
96.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-24
Biocryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Transcript
Confident tone
Pediatric Orladeo label expansion
BCX1775 for Netherton syndrome
Medicare / Inflation Reduction Act impact
Revenue
$131.53M*
▲ 40.8% YoY Gross margin
95.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Biocryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Transcript
Confident tone
BCX17725 for Netherton Syndrome Pipeline
Pediatric Label Expansion and ORLADEYO Granules
Medicare and Non-Commercial Access Risks
Revenue
$117.08M
▲ 35% YoY Diluted EPS
$-0.07
Gross margin
97.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Biocryst Pharmaceuticals Inc (BCRX) Q2 2024 Earnings Call Transcript
Confident tone
ORLADEYO Commercial Performance
2024 Revenue Guidance Raise
Long-Term $1B Peak Sales Opportunity
Revenue
$109.33M
▲ 32.5% YoY Diluted EPS
$-0.06
Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Biocryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript
Confident tone
ORLADEYO commercial performance
Pipeline advancement
Pediatric program and filing
Revenue
$92.76M
▲ 34.9% YoY Diluted EPS
$-0.17
Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Biocryst Pharmaceuticals Inc (BCRX) Q4 2023 Earnings Call Transcript
Confident tone
ORLADEYO Commercial Performance
Real-World Evidence and Clinical Data
HAE Market Dynamics
Revenue
$93.40M*
▲ 17.4% YoY Gross margin
98.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Biocryst Pharmaceuticals Inc (BCRX) Q3 2023 Earnings Call Transcript
Revenue
$86.74M
▲ 14.4% YoY Diluted EPS
$-0.19
Gross margin
98.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Biocryst Pharmaceuticals Inc (BCRX) Q2 2023 Earnings Call Transcript
Revenue
$82.49M
▲ 25.9% YoY Diluted EPS
$-0.40
Gross margin
98.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Biocryst Pharmaceuticals Inc (BCRX) Q1 2023 Earnings Call Transcript
Revenue
$68.78M
▲ 37.8% YoY Diluted EPS
$-0.28
Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Biocryst Pharmaceuticals Inc (BCRX) Q4 2022 Earnings Call Transcript
Revenue
$79.55M*
▲ 68.7% YoY Gross margin
97.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Biocryst Pharmaceuticals Inc (BCRX) Q3 2022 Earnings Call Transcript
Revenue
$75.83M
▲ 85% YoY Diluted EPS
$-0.23
Gross margin
95.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Biocryst Pharmaceuticals Inc (BCRX) Q2 2022 Earnings Call Transcript
Revenue
$65.53M
▲ 31.2% YoY Diluted EPS
$-0.32
Gross margin
99.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Biocryst Pharmaceuticals Inc (BCRX) Q1 2022 Earnings Call Transcript
Revenue
$49.92M
▲ 161.9% YoY Diluted EPS
$-0.40
Gross margin
99.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Biocryst Pharmaceuticals Inc (BCRX) Q4 2021 Earnings Call Transcript
Revenue
$47.16M*
▲ 1074.3% YoY Gross margin
99.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Biocryst Pharmaceuticals Inc (BCRX) Q3 2021 Earnings Call Transcript
Revenue
$40.99M
▲ 571.8% YoY Diluted EPS
$-0.33
Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Biocryst Pharmaceuticals Inc (BCRX) Q2 2021 Earnings Call Transcript
Revenue
$49.96M
▲ 1640.1% YoY Diluted EPS
$-0.24
Gross margin
99.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Biocryst Pharmaceuticals Inc (BCRX) Q1 2021 Earnings Call Transcript
Revenue
$19.06M
▲ 295.2% YoY Gross margin
68.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Biocryst Pharmaceuticals Inc (BCRX) Q4 2020 Earnings Call Transcript
Revenue
$4.02M
▼ 89.9% YoY Gross margin
99.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Biocryst Pharmaceuticals Inc (BCRX) Q3 2020 Earnings Call Transcript
Revenue
$6.10M
▲ 243.8% YoY Gross margin
75.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Biocryst Pharmaceuticals Inc (BCRX) Q2 2020 Earnings Call Transcript
Revenue
$2.87M
▲ 98.3% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Biocryst Pharmaceuticals Inc (BCRX) Q1 2020 Earnings Call Transcript
Revenue
$4.82M
▼ 18.1% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Biocryst Pharmaceuticals Inc (BCRX) Q4 2019 Earnings Call
Revenue
$39.73M
▲ 1355.7% YoY Gross margin
94.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 webcasts
Key facts
CIK
882796
CUSIP
09058V103
13F (30d)
246 filings
226 filers
Visit website
Investor relations